WO2008076826A1 - Agents d'alkylation pyrophosphoramide - Google Patents
Agents d'alkylation pyrophosphoramide Download PDFInfo
- Publication number
- WO2008076826A1 WO2008076826A1 PCT/US2007/087429 US2007087429W WO2008076826A1 WO 2008076826 A1 WO2008076826 A1 WO 2008076826A1 US 2007087429 W US2007087429 W US 2007087429W WO 2008076826 A1 WO2008076826 A1 WO 2008076826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- pyrophosphoramide
- alkylator
- Prior art date
Links
- 239000002168 alkylating agent Substances 0.000 title abstract description 47
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Chemical group O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 150000003222 pyridines Chemical class 0.000 claims description 5
- 125000005270 trialkylamine group Chemical group 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 12
- 229940125904 compound 1 Drugs 0.000 description 53
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 31
- -1 4-hydroxyphenylsulfonyloxy moiety Chemical group 0.000 description 24
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 9
- 229960001101 ifosfamide Drugs 0.000 description 9
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 0 *N(*)P(N(*)*)(Cl)=O Chemical compound *N(*)P(N(*)*)(Cl)=O 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- FUNYDODCWWGJJA-UHFFFAOYSA-N bis(2-bromoethylamino)phosphinic acid Chemical compound BrCCNP(=O)(O)NCCBr FUNYDODCWWGJJA-UHFFFAOYSA-N 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229940127084 other anti-cancer agent Drugs 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- ONRREFWJTRBDRA-UHFFFAOYSA-N 2-chloroethanamine;hydron;chloride Chemical compound [Cl-].[NH3+]CCCl ONRREFWJTRBDRA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229910004856 P—O—P Inorganic materials 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical group CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 125000005596 alkyl carboxamido group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000005025 clonogenic survival Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical class NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- RDWBWBOPAWKJAZ-UHFFFAOYSA-N n-(ethylamino)-n-(methylamino)propan-1-amine Chemical compound CCCN(NC)NCC RDWBWBOPAWKJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 208000012028 nasolacrimal duct disease Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004351 phenylcyclohexyl group Chemical group C1(=CC=CC=C1)C1(CCCCC1)* 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000007079 thiolysis reaction Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
Definitions
- the present invention provides compositions and methods for treating cancer and other hyperproliferative disease conditions with pyrophosphoramide alkylators alone and in combination with other anti-cancer agents and therapies, and so relates to the fields of medicine, pharmacology, chemistry, and biology.
- Phosphoramidate alkylators used in treating cancer encompass a group of compounds that have in common the ability to alkylate biologically vital macromolecules such as DNA (Hardman et al., The Pharmacological Basis of Therapeutics, 2001 , 1389-1399, McGraw-Hill, New York, USA).
- certain prodrugs currently used in cancer therapy that release phosphoramidate alkylators in vivo such as the drugs ifosfamide and cyclophosfamide, are problematic due to side effects arising in part from toxic metabolites such as acrolein.
- a phosphoramidate alkylator prodrug, giufosfamide, that does not produce acrolein, has not yet been approved for treating cancer (see, US Pat. No. 5,622,936 incorporated herein by reference).
- the present invention provides pyrophosphoramide alkylators that are anhydrides of phosphoramidate alkylators containing 1 -3 phosphoramidate alkylator moieties.
- the present invention provides pyrophosphoramide alkylators containing two phosphoramidate alkylator moieties.
- each of the phosphoramidate alkylator moieties is selected from the group consisting of an ifosfamide alkylator, a cyclophosfamide alkylator, an N,N,N',N'-tetrakis-2-haloalkyl phosphoramidate alkylator, and analogs of the foregoing.
- the pyrophosphoramide alkylator is a bis-ifsofamide alkylator.
- the present invention provides phosphoramidate alkylator anhydrides containing two phosphoramidate alkylator moieties joined by a phosphate or a phosphoramidate moiety.
- the present invention provides a pyrophosphoramide alkylator having a structure of formula:
- each R 1 - R 8 is independently selected from the group consisting of H, C- ⁇ -C- 6 alkyl, and the moiety:
- each Rg- R 11 is O.
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- the present invention provides a pyrophosphoramide alkylator having structure of formula: H R 8
- R 4 H "R 6 or a pharmaceutically acceptable salt thereof; wherein R 2 , R 4 , Re, and R 8 are defined as above.
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- R 12 is selected from the group consisting of halo and OSO 2 R I4 -
- R 12 is selected from the group consisting of chloro and bromo.
- R 12 is a 4-hydroxyphenylsulfonyloxy moiety:
- the present invention provides a pyrophosphoramide alkylator of the present invention in substantially pure form.
- the present invention provides methods of synthesizing novel pyrophosphoramide alkylators and known pyrophosphoramide compounds, comprising reacting a phosphoramidate alkylator or a phosphoramidate under Mitsunobu conditions.
- the present invention provides methods of synthesizing novel pyrophosphoramide alkylators and known pyrophosphoramide compounds, comprising reacting a phosphoramidate alkylator or a phosphoramidate with a dialkyl or dicycloalkyl carbodiimide.
- the present invention provides methods of synthesizing novel pyrophosphoramide alkylators and known pyrophosphoramide compounds, comprising reacting a compound having a structure of formula:
- a pharmaceutically acceptable salt thereof with water and a base selected from the group consisting of a trialkyl amine and a pyridine.
- the present invention provides a pharmaceutically acceptable formulation comprising a pyrophosphoramide alkylator and pharmaceutically acceptable diluents or excipients.
- the present invention provides a method of treating cancer and other hyperproliferative diseases comprising administering a therapeutically effective amount of a pyrophosphoramide alkylator to a patient in need of such treatment.
- Figure 1 Tumor growth delay in H460 tumor xenografts in mice, upon administration of compound 1 alone and in combination with cisplatin (CDDP)
- Section I provides useful definitions
- Section Il describes pyrophosphoramide alkylators of the present invention (part A) and methods of synthesizing novel and known pyrophosphoramide compounds (part B);
- Section III describes various methods of treating cancer and other diseases of cellular hyperproliferation employing the pyrophosphoramide alkylators of the present invention;
- Section IV provides illustrative examples for synthesizing pyrophosphoramide alkylators of the present invention and demonstrating in vitro and in vivo efficacy of a pyrophosphoramide alkylator of the present invention.
- This detailed description is organized into sections only for the convenience of the reader, and disclosure found in any section is applicable to disclosure elsewhere in the specification.
- C 1 -C 6 alkoxy refers to a Ci-C ⁇ alkyl covalently bonded to an oxygen atom.
- a C-1-C 6 alkoxy group has the general structure -0-(Cr Ce)alkyl.
- C I -C ⁇ alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
- CrC ⁇ alkoxycarbonyl refers to a CrC 6 alkoxy group covalently bonded to a carbonyl.
- C 1 -Ce alkyl refers to a substituted or unsusbstituted straight or branched chain alkyl groups having 1-6 carbon atoms.
- C 1 -C- 6 alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2- pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl.
- a C r C 6 alkyl substituent may be covalently bonded to an atom within a molecule of interest via any chemically suitable portion of the CrC 6 alkyl group.
- CrC ⁇ alkylamino refers to a CrC ⁇ alkyl covalently bonded to -NH- .
- a CrC 6 alkylamino group has the general structure -NH-(Cr C 6 )alkyl.
- a di(C r C 6 )alkylamino group has the general structure -N-[(C r C 6 )alkyl] 2 .
- CrC 6 alkylamino groups include, for example, methylamino, ethylamino, propylamine and butylamino.
- CrCe alkylene refers to a linear saturated divalent substituted or unsubstituted hydrocarbon radical or a branched saturated divalent hydrocarbon radical having 1 - 6 carbon atoms.
- An alkylene can be further substituted with Cr Ce alkyl and aryl groups.
- Alkylene groups include, for example, methylene, ethylene, propylene, butylene, 2-methylpropylene, pentylene.
- Cycloalkyl refers to a substitutued or unsubstitutued monovalent cyclic hydrocarbon group of three to seven ring carbons.
- the cycloalkyl group can have one or more double bonds and can be further substituted with C 1 -C 6 alkyl and aryl groups.
- the term cycloalkyl includes, for example, cyclopropyl, cyclohexyl, cyclohexenyl, phenylcyclohexyl, 4-carboxycyclohexyl, 2- carboxamidocyclohexenyl, 2-dimethylaminocarbonyl-cyclohexyl, and the like.
- Aryl refers to a substituted or unsusbstituted moiety that includes one or more monocyclic or fused ring aromatic systems. Such moieties include any moiety that has one or more monocyclic or bicyclic fused ring aromatic systems, including but not limited to phenyl and naphthyl.
- Halogen or halo refers to fluorine, chlorine, bromine, and iodine.
- Heteroaryl refers to a substituted or unsusbstituted monocyclic aromatic system having 5 or 6 ring atoms, or a fused ring bicyclic aromatic system having 8 - 20 atoms, in which the ring atoms are C, O, S, SO, SO 2 , or N and at least one of the ring atoms is a heteroatom, i.e., O, S, SO, SO 2 , or N.
- Heteroaryl groups include, for example, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothio- furanyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl
- Heterocyclyl refers to a substituted or unsubstituted monocyclic or fused ring multicyclic cycloalkyl group at least a portion of which is not aromatic and in which one or more of the carbon atoms in the ring system is replaced by a heteroatom selected from the group consisting of O, S, SO, SO 2 , P, or N.
- heterocyclyl groups include but are not limited to imidazolinyl, morpholinyl, piperidinyl, piperidin-2-only, piperazinyl, pyrrol id inyl, pyrrolidine-2- onyl, tetrahydrofuranyl, and tetrahydroimidazo [4,5-c] pyridinyl.
- C 1 -C 6 heteroalkylene refers to a CrC 6 alkylene as defined above wherein 1 - 3 carbon atoms in the hydrocarbon radical or a branched saturated divalent hydrocarbon radical is replaced with a heteroatom.
- Ci-C 6 heteroalkylene groups include, for example, -CH 2 CH 2 -O-CH 2 CH 2 - and -CH 2 CH 2 -S-CH 2 CH 2 -.
- C 1 -C 6 heteroalkyl refers to a C 1 -C 6 alkyl as defined above wherein 1 - 3 carbon atoms in the hydrocarbon radical or a branched saturated divalent hydrocarbon radical is replaced with a heteroatom.
- C 1 -C 6 heteroalkyl groups include, for example, -CH 2 CH 2 -O-CH 2 CH 3 and -CH 2 CH 2 -S-CH 2 CH 3 .
- Phosphoramidate alkylators refer to phosphordiamidic acid compounds (or mustards) having up to four substituted or unsubstituted -CH 2 -CH 2 -X moieties, wherein X is selected from the group consisting of halo and an 0-SO 2 - Y moiety wherein Y is CrC 6 alkyl, CrC 6 heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- Phosphoramidate alkylators include, for example, ifosfamide alkylator, dibromoifosfamide alkylator, cyclophosfamide alkylator, and N, N, N', N' -tetrakis-2-haloalkyl phosphoramidate alkylators. Examples of other phosphoramidate alkylators are provided in PCT Patent App. Pub. No. WO 07/002931 and US Pat. No. 6,197,760 each of which is incorporated herein by reference.
- “Pyrophosphoramide alkylators” refer to linear or cyclic anhydrides of phosphoramidate alkylators containing two or more phosphoramidate alkylator moieties.
- Substituent refers to an atom or group, including, for example, amino, C-i-C ⁇ alkylamino or di(C- ⁇ -C 6 )alkylamino, C-i-C ⁇ alkoxy, C-1-C 6 alkylthio, aryl, - COOH, -CONH 2 , cyano, ethenyl, ethynyl, halo, heteroaryl, hydroxy, mono- or di(Ci-C 6 )alkylcarboxamido, mono or d ⁇ CrC ⁇ alkylsulfonamido, nitro, -OSO 2 -(Cr C 6 )alkyl, and -SO 2 NH 2 .
- administering or “administration of” a drug to a patient (and grammatical equivalents of this phrase) refers to direct administration, which may be administration to a patient by a medical professional or may be self- administration, and/or indirect administration, which may be the act of prescribing a drug. For example, a physician who instructs a patient to self-administer a drug and/or provides a patient with a prescription for a drug is administering the drug to the patient.
- “About” refers to ⁇ 20% of a quantity and includes, but is not limited to, ⁇ 15%, ⁇ 10%, and ⁇ 5%.
- Cancer refers to leukemias, lymphomas, and malignant tumors of potentially unlimited growth that can expand locally by invasion and systemically by metastasis.
- cancers include, but are not limited to cancer of the adrenal gland, bone, brain, breast, bronchi, colon and/or rectum, gallbladder, head and neck, kidneys, larynx, liver, lung, neural tissue, pancreas, prostate, parathyroid, skin, stomach, and thyroid.
- cancers include, acute and chronic lymphocytic and granulocytic tumors, adenocarcinoma, adenoma, basal cell carcinoma, cervical dysplasia and in situ carcinoma, Ewing's sarcoma, epidermoid carcinomas, giant cell tumor, glioblastoma multiforma, hairy-cell tumor, intestinal ganglioneuroma, hyperplastic corneal nerve tumor, islet cell carcinoma, Kaposi's sarcoma, leiomyoma, leukemias, lymphomas, malignant carcinoid, malignant melanomas, malignant hypercalcemia, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuroma, myeloma, mycosis fungoides, neuroblastoma, osteo sarcoma, osteogenic and other sarcoma, ovarian tumor, pheochromocytoma, polycythemia vera, primary brain tumor, small-
- Hyperproliferative disease refers to a disease characterized by cellular hyperproliferation (e.g., an abnormally increased rate or amount of cellular proliferation).
- hyperproliferative diseases other than cancer include, but are not limited to, allergic angiitis and granulomatosis (Churg-Strauss disease), asbestosis, asthma, atrophic gastritis, benign prostatic hyperplasia, bullous pemphigoid, coeliac disease, chronic bronchitis and chronic obstructive airway disease, chronic sinusitis, Crohn's disease, demyelinating neuropathies, dermatomyositis, eczema including atopic dermatitis, eustachean tube diseases, giant cell arteritis, graft rejection, hypersensitivity pneumonitis, hypersensitivity vasculitis (Henoch-Schonlein purpura), irritant dermatitis, inflammatory hemolytic anemia, inflammatory neutropenia, inflammatory bowel disease
- “Pharmaceutically acceptable carrier, excipient, or diluent” refers to a carrier, excipient, or diluent that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier, excipient, or diluent that is acceptable for veterinary use as well as human pharmaceutical use.
- a “pharmaceutically acceptable carrier, excipient, or diluent” includes one and more than one such carrier, excipient, or diluent.
- Prodrug refers to a compound that, after administration, is metabolized or otherwise converted to a biologically active or more active compound (or drug) with respect to at least one property.
- a prodrug, relative to the drug is modified chemically in a manner that renders it, relative to the drug, less active or inactive, but the chemical modification is such that the corresponding drug is generated by metabolic or other biological processes after the prodrug is administered.
- a prodrug may have, relative to the active drug, altered metabolic stability or transport characteristics, fewer side effects or lower toxicity, or improved flavor (for example, see the reference Nogrady, 1985, Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392, incorporated herein by reference).
- a prodrug may be synthesized using reactants other than the corresponding drug.
- Reduction of a symptom or symptoms refers to decreasing the severity or frequency of the symptom(s), or elimination of the symptom(s).
- “Therapeutically effective amount" of a drug refers to an amount of a drug that, when administered to a subject with cancer or another hyperproliferative disease, will have the intended therapeutic effect, e.g., alleviation, amelioration, palliation or elimination of one or more manifestations of cancer or another hyperproliferative disease in the subject.
- the full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations.
- Treating" a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results.
- beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms of cancer or another hyperproliferative disease; diminishment of extent of disease; delay or slowing of disease progression; amelioration, palliation, or stabilization of the disease state, or other beneficial results described more particularly below.
- Phosphoramidate alkylators have been used in treatment of cancer. Because of the reactivity and instability of the phosphoramidate alkylators, these alkylators are administered as prodrugs that are more stable than their corresponding alkylators. Upon administration, the phosphoramidate alkylator prodrugs are metabolized, releasing the alkylator, which kills cancer cells. For example, cyclophosfamide, a prodrug of cyclophosfamide alkylator, and ifosfamide, a prodrug of ifosfamide alkylator, are used in cancer treatment.
- cyclophosfamide and ifosfamide prodrugs are problematic, because when metabolized, they produce the toxic byproduct acrolein, which can cause unwanted side effects.
- the present invention arises in part out of the discovery that anhydrides of phosphoramidate alkaylators such as pyrophosphoramides are excellent prodrugs.
- an ionizable hydroxyl group, "P-OH” is converted into a "P-O-P” type, charge neutral, oxygen atom.
- the pyrophosphoramide alkylator is more stable to hydrolysis, aminolysis, and/or thiolysis, compared to the corresponding phosphoramidate alkylator.
- the "P-O-P" linker is hydrolyzed and the phosphoramidate alkylator is released and can kill cancer cells.
- the present invention provides anhydrides of phosphoramidate alkylators containing two or more phosphoramidate alkylator moieties. In one embodiment, the present invention provides pyrophosphoramide alkylators containing two phosphoramidate alkylator moieties. In another embodiment, the present invention provides pyrophosphoramide alkylators wherein each of the phosphoramidate alkylator moieties is the same. In another embodiment, the present invention provides pyrophosphoramide alkylators wherein each of the alkylator moieties is different.
- each of the alkylator moieties is an ifosfamide alkylator, a dibromoifosfamide alkylator, a cyclophosfamide alkylator, an N,N,N',N'-tetrakis-2-haloalkyl phosphoramidate alkylator, or an analog of one of the foregoing.
- the pyrophosphoramide alkylator is a bis-ifsofamide alkylator.
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- each R 1 - R 8 is independently selected from the group consisting of H, C 1 -Ce alkyl, and the moiety:
- each Rg- R 1 I is O.
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- R 2 , R 4 , R 6 , and Rs are defined as above.
- the present invention provides a pyrophosphoramide alkylator having structure of formula:
- R 12 is selected from the group consisting of halo and OSO 2 R 14 .
- R 12 is selected from the group consisting of chloro and bromo.
- R 12 is a 4-hydroxyphenylsulfonyloxy moiety:
- n O - 4 and R 16 is selected from the group consisting of halo, cyano, nitro, C 1 -C 6 alkyl, CrC 6 heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- a 4-hydroxyphenylsulfonyloxy moiety can be ionized to a phenoxide anion at neutral pH and be charge neutral at lower pH. Extracellular regions of tumors reportedly have lower pH compared to that of normal tissue.
- a pyrophosphoramide alkylator containing a 4- hydroxyphenylsulfonyloxy moiety as a leaving group can exist in the extracellular region of a tumor in its charge neutral form.
- the charge neutral form can permeate through the cell membrane more easily than the ionized anionic form and thus, pyrophosphoramide alkylators containing one or more 4-hydroxyphenylsulfonyloxy moieties can selectively enter into and kill tumor cells compared to normal cells.
- pyrophosphoramide alkylators of the present invention examples include:
- the present invention provides pharmaceutically acceptable formulations comprising the pyrophosphoramide alkylators of the present invention.
- the pharmaceutically acceptable formulations further comprise a suitable carrier, excipient, or diluent.
- the pyrophosphoramide compounds of the present invention can be synthesized by reacting a phosphoramidate alkylator with a trisubstitutued phosphine and a dialkylazdicarboxylate under Mitsunobu reaction conditions.
- the present invention provides methods of synthesizing novel pyrophosphoramide alkylators and known pyrophosphoramide compounds comprising, reacting a phosphoramidate alkylator or a phosphoramidate; a trisubstituted phosphine; and a dialkylazodicarboxylate.
- the method comprises reacting a phosphoramidate alkylator having a structure of formula:
- R-i - R 4 is defined as above, under reaction conditions described as above.
- R 1 and R 3 are hydrogen.
- each R 2 and R 4 is independently selected from the group consisting of 2-chloroethyl, 2-bromoethyl, and -CH 2 - CH 2 -OSO 2 R 14 wherein R 14 is defined as above.
- the trisubstitued phosphine is selected from the group consisting of from triphenyl phosphine, tributyl phosphine, and a resin bound triphenyl phosphine.
- the dialkylazodicarboxylate is selected from diethylazodicarboxylate and diisopropylazodicarboxylate.
- pyrophosphoramide alkylators are synthesized by reacting phosphoramidate alkylators, a dicycloalkyl or dialkylcarbodiimide, and optionally, amines such as a trialkylamine and/or a 4-dialkylaminopyridine.
- amines such as a trialkylamine and/or a 4-dialkylaminopyridine.
- the pyrophosphoramide alkylators are synthesized by reacting a compound having a structure of formula:
- a pyrophosphoramide alkylator of the present invention in accordance with this method of the present invention is schematically shown below and can be used for synthesizing other pyrophosphoramide alkylators of the present invention:
- Suitable bases useful in the method include, but are not limited to trialkyl amines and pyridines.
- Other pyrophosphoramide alkylator of the present invention can be synthesized following the method described above by appropriate substitution of starting material.
- the present invention provides a method of synthesizing a pyrophosphoramide alkylator of the present invention having a structure of formula:
- Ri 2 is selected from the group consisting of halo and OSO 2 R 14 wherein R 14 is selected from the group consisting of C 1 -C 6 alkyl, C-i-C ⁇ heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl comprising reacting a compound having a structure of formula: or a pharmaceutically acceptable salt thereof; a base selected from the group consisting of a trialkylamine and a pyridine analog, and water to yield the compound having a structure of formula:
- R-12 is chloro. In another embodiment, R 12 is bromo. In another embodiment, the amine is triethyl amine. In one embodiment, the pyridine analog is a 4-N,N-dialkylaminopyridine. The synthesis of Compound 2 according to this method is described in Section IV.1. B.
- Compounds 1-4 can be synthesized by a Mitsunobu reaction employing triphenyl phosphine and diisopropyl or diethyl azodicarboxylate.
- Pyrophosphoramide alkylators of the present invention can also be synthesized following synthetic methods reported, for example, in PCT Patent App. Pub. No. WO 07/002931 ; US Pat. No. 4,518,413; and GB 985,996 (each of which is incorporated herein by reference), modified in accordance with the teachings herein and appropriate substitution of starting material.
- Compound 1 a pyrophosphoramide alkylator of the present invention, was effective in treating cancer as demonstrated by treating various xenograft solid tumors in mice, when administered alone and in combination with a variety of other anticancer agents.
- Suitable anticancer agents, useful in combination with Compound 1 included, CDDP and gemcitabine.
- Various modes of administration and dosing schedules were found to be effective in the treatment of cancer. These and other monotherapies and combination therapies for administering Compound 1 are described in Examples 5.A - C below.
- the present invention provides a method of treating cancer and other hyperproliferative diseases comprising administering a therapeutically effective amount of a pyrophosphoramide alkylator of the present invention to a patient in need of such treatment.
- the present invention provides a method of treating cancer and other hyperproliferative diseases comprising administering a therapeutically effective amount of a pyrophosphoramide alkylator of the present invention having structure of formula:
- the pyrophosphoramide alkylator administered has the structure of formula:
- the pyrophosphoramide alkylator administered is compound 1.
- the pyrophosphoramide alkylators of the present invention are administered in the form of pharmaceutically acceptable formulations.
- the pharmaceutical formulations are administered parenteraliy or orally (p.o.).
- the pharmaceutical formulations are administered by i.v. or i.p. injection or by infusion.
- the pyrophosphoramide alkylators of the present invention can be administered in accordance with any of a variety of dosing schedules including but not limited to daily or once every other day or once a week to the patient. Multiple daily administrations of a pyrophosphoramide alkylator of the present invention can also be employed in the methods of the invention. Depending on the dose selected by the practitioner and the convenience of the patient, the entire daily dose may be administered once daily or the daily dose may be administered in multiple smaller doses throughout the course of a day.
- the pyrophosphoramide alkylators of the present invention need not, however, be administered daily; for example a daily dose used for some patients or indications may be, in other patients or for other indications, given every other day, or less frequently.
- the daily dose is repeatedly administered over a period of time.
- the administration of the therapeutically effective daily dose is continued for multiple days, typically for at least three consecutive days, or for at least a week, or for several weeks, or for several months, or for several years, or until cancer (or another hyperproliferative disease) or one or more of its symptoms disappears or substantially abates, or up to the rest of the patient's life.
- cancer or another hyperproliferative disease
- treatment can be suspended temporarily if toxicity is observed or for the convenience of the patient without departing from the scope of the invention.
- the pyrophosphoramide alkylators of the present invention are administered qd, bid, tid, qid, qod, q2d, twice weekly, q7d, or qweek, and treatment is continued for a period ranging from three days to the longer periods enumerated above.
- the methods of the present invention can be used for treatment of any cancer.
- the compound of the present invention is administered for the treatment of cancer in combination with other anti cancer agents or other anti cancer therapies.
- Suitable anticancer therapies useful in accordance with the present methods include, but are not limited to, radiation therapy and surgery.
- the present invention provides a method of treating hyperproliferative diseases characterized by cellular hyperproliferation (e.g., an abnormally increased rate or amount of cellular proliferation) other than cancer, by administering a therapeutically effective amount of a pyrophosphoramide alkylator to a patient in need of such treatment.
- hyperproliferative diseases characterized by cellular hyperproliferation (e.g., an abnormally increased rate or amount of cellular proliferation) other than cancer, by administering a therapeutically effective amount of a pyrophosphoramide alkylator to a patient in need of such treatment.
- This example describes the synthesis of compound 1 , a novel pyrophosphoramide alkylator of the present invention, from dibromoifosfamide alkylator (Br-IPM) and DCC.
- a mixture of Br-IPM (1.24 g, 4 mmol) and dicyclohexylcarbodiimide (DCC, 1.24 g, 6 mmol) in THF (20 ml_) was stirred at room temperature (rt). After 2 h, thin layer chromatography (15:1 (v/v) ethyl acetate/methanol) of the reaction mixture showed that the reaction was completed.
- Compound 1 can be synthesized employing this method and substituting 2-chloroethylamine hydrochloride with 2-bromoethylamine hydrobromide.
- H460 cells ATCC HTB-177 (NCI- H460), 20,000 cells/well/500 ⁇ l_
- RPMI medium Invitrogen Corp.
- the cells in the treatment group were rinsed to remove compound 1 , further incubated for 3 days, and then stained with Alamar blue for 2 h.
- the cells were stained with Alamar blue for 2 h.
- the IC 50 of compound 1 was calculated from the plot as the concentration of compound 1 at which there was a 50% reduction in cell proliferation compared to the control group. See Biosource International Inc., Tech Application Notes, Use of Alamar Blue in the Measurement of Cell Viability and Toxicity, Determining IC 50 .
- the antiproliferative activity of compound 1 was determined in HT29, PC3, and MiaPaCa-2 cell lines in the same way as described above for the H460 cell line.
- test compound 1 can be incubated with the test compound, compound 1 , at various concentrations for 3 days and the antiproliferation activity of the test compound determined as described above for the 2h treatment group.
- the results from these tests are tabulated below (Table 1 , average value of IC 50 presented, if multiple tests were done with one cell line). This method can be employed to measure the antiproliferative activities of other compounds of the present invention.
- This example demonstrates the cytotoxic property of compound 1 by determining clonogenic cell survival.
- Exponentially growing human colon cancer HT29 cells obtained from the ATCC
- HT29 cells obtained from the ATCC
- RPMI medium supplemented with 10 % fetal bovine serum for 2 days prior to initiating drug treatment.
- solutions of Compound 1 of known concentration were prepared in complete medium, 2 mL of the desired solution added to each plate, and the cells were incubated under an atmosphere of 95% air and 5% carbon dioxide for 2 h at 37°C. Then, the cells were rinsed to remove compound 1.
- the glass plates were washed with phosphate buffered saline and a solution of trypsin-EDTA and then trypsinized at 37 0 C for 5 min. Detached cells were neutralized with medium and serum, collected by centrifugation at 100xg for 5 min, resuspended at approximately 1x10 6 cells/mL, and diluted 10 fold to yield stock concentrations of treated cells for plating. The concentration of each stock was determined by counting with a Coulter Z2 particle counter. Known numbers of cells were plated, and the plates were placed in an incubator for between 7 and 10 days. Colonies were fixed and stained with a solution of 0.25% crystal violet in 95% ethanol. Colonies of greater than 50 cells were counted.
- the surviving fraction of treated cells was measured by comparison with colony numbers obtained from untreated cells, and the concentration of compound 1 at which 10% cells survived (or 90% cell death), or IC 90 determined. See Table 1 below. This method can be employed to measure the cytotoxicities of other compounds of the present invention. Table 1
- cancer such as, non small cell lung cancer
- a compound of the present invention can be administered in an amount in a range of about 0.01 mg/kg - about 60 mg/kg and about 0.06 mg/kg - about 6 mg/kg for treating cancer in humans.
- H460 xenograft tumor bearing mice were treated with Compound 1 orally at 200 mg/kg once or at 50 mg/kg, everyday for 5 days.
- the monotherapy, i.e., a single agent administration, of Compound 1 at 50 mg/kg daily dosing demonstrated similar tumor growth inhibition as CDDP alone.
- the monotherapy of Compound 1 at 200 mg/kg single dose demonstrated a higher tumor growth inhibition than Compound 1 dosed once daily.
- the combination therapy administering Compound 1 at 200 mg/kg single dose and at 50 mg/kg once daily dosing resulted in a similar tumor growth inhibition.
- the TGDs as compared to vehicle treated tumors, to reach 500 mm 3 , were 6 and 7 days respectively, when Compound 1 was administered alone at 200 mg/kg and 50 mg/kg; they were 12 and13 days respectively when Compound 1 was administered at the same amount and in combination with CDDP. Tumor growth was inhibited 56% and 64% when Compound 1 was administered alone at 200 mg/kg and 50 mg/kg, and 84% and 85% when Compound 1 administered at the same amount was co-administered with CDDP. Animals in the drug treated groups lost weight during the treatment period, but recovered after dosing stopped, demonstrating that the administration of Compound 1 , in accordance with the present methods is effective and safe for the treatment of cancer. C.
- Compound 1 when administered orally, to treat xenografted H460 lung tumor in nude mice, by administering Compound 1 as a monotherapy, and in combination with gemcitabine.
- Compound 1 was formulated (2.5, 5, and 20 mg/ml_) in a vehicle (2% DMSO, 0.5% Tween ⁇ O, and 0.5% carboxymethyl cellulose (CMC) in water).
- Gemcitabine (6 mg/mL) was formulated in saline. The drug formulations were prepared weekly, stored at 4 0 C, and diluted prior to administration.
- H460 cells were prepared in 50% matrigel and 50% PRIM medium and were implanted (1 x 10 6 . 0.2 mL/mouse) subcutaneously on the right flank of the mice. Tumor lumps were measurable on the seventh day post-implantation and were about 100 mm 3 on the eleventh day.
- Mice with similar tumor size were randomized for treatment and treated as follows: Compound 1 was administered orally (p.o.), once every day for 5 days/week for 2 weeks (qd x 5 x 2 weeks) at amounts of 25 and 50 mg/kg, and once every week for 2 weeks at amounts of 200 mg/kg, alone, and in combination with gemcitabile (i.p., 60 mg/kg, q3dx4); in all 6 groups of 10 mice each were thus treated. A group of 10 tumor bearing mice were used as no-treatment control. The results of tumor growth inhibition upon administration of Compound 1 alone and in combination are tabulated below.
- T/C (Tn-Ti)/(Cn-Ci)
- Tn tumor volume in treatment group at Day 31
- Ti is the initial tumor volume in the treatment group
- Cn tumor volume in the vehicle control group at Day 31
- Ci is the initial tumor volume in the vehicle control group.
- TGI tumor growth inhibition
- the drug treated groups showed weight loss during the treatment period, but recovered after drug administration was stopped.
- the administration of Compound 1 according to the present methods was effective and safe to treat the tumors.
- Compound 1 was administered to mice bearing HT29 xenograft tumor, alone and in combination with CPT-11 , the results indicated that Compound 1 was more effective in treating mice bearing H460 xenograft tumor than mice bearing HT29 tumor.
- human equivalent doses can be estimated from doses administered to mice by dividing the mouse dose by -12.
- a compound of the present invention can be administered in a daily dose in the range of about 0.02 mg/kg - about 1700 mg/kg and about 0.2 mg/kg - about 170 mg/kg for treating cancer in humans.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des agents d'alkylation pyrophosphoramide utiles dans le traitement du cancer et d'autres maladies hyperprolifératives.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87486906P | 2006-12-13 | 2006-12-13 | |
US60/874,869 | 2006-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008076826A1 true WO2008076826A1 (fr) | 2008-06-26 |
Family
ID=39536682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/087429 WO2008076826A1 (fr) | 2006-12-13 | 2007-12-13 | Agents d'alkylation pyrophosphoramide |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008076826A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8299088B2 (en) | 2003-03-28 | 2012-10-30 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4203977A (en) * | 1977-10-13 | 1980-05-20 | Basf Aktiengesellschaft | Phosphoric acid esters, composition and use |
US4661509A (en) * | 1982-09-28 | 1987-04-28 | Gordon Arnold Z | Methods for treating leukopenia |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
WO2006103568A2 (fr) * | 2005-03-22 | 2006-10-05 | Innate Pharma | Nouvelle classe d'activateurs de cellules g? t et utilisation correspondante |
-
2007
- 2007-12-13 WO PCT/US2007/087429 patent/WO2008076826A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4203977A (en) * | 1977-10-13 | 1980-05-20 | Basf Aktiengesellschaft | Phosphoric acid esters, composition and use |
US4661509A (en) * | 1982-09-28 | 1987-04-28 | Gordon Arnold Z | Methods for treating leukopenia |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
WO2006103568A2 (fr) * | 2005-03-22 | 2006-10-05 | Innate Pharma | Nouvelle classe d'activateurs de cellules g? t et utilisation correspondante |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299088B2 (en) | 2003-03-28 | 2012-10-30 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8507464B2 (en) | 2005-06-29 | 2013-08-13 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8664204B2 (en) | 2005-06-29 | 2014-03-04 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US9226932B2 (en) | 2005-06-29 | 2016-01-05 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2613312C (fr) | Prodrogues d'alkylateur de phosphoramidate | |
WO2008151253A1 (fr) | Promédicaments d'agents antinéoplasiques activés par l'hypoxie | |
WO2009018163A1 (fr) | Promédicaments d'anthracyclines activés par une hypoxie | |
EP4011871A2 (fr) | Procédés de préparation de composés de type oxathiazine | |
TW201831191A (zh) | 一種新的硼酸衍生物及其藥物組合物 | |
AU2005286833B2 (en) | Sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
WO2008076826A1 (fr) | Agents d'alkylation pyrophosphoramide | |
WO2009033165A1 (fr) | Promédicaments activés par l'hypoxie à base d'agents bis-alkylants | |
WO2008011588A2 (fr) | Glycoconjugués d'alkylateurs de phosphoramidate pour le traitement du cancer | |
ES2227225T3 (es) | Compuestos de rutenio (ii) para utilizar en la terapia del cancer. | |
JP4598227B2 (ja) | 放射線および化学療法における感受性増強剤である化合物、並びにそれらの製造方法および使用 | |
WO2013146437A1 (fr) | Dérivé de l'acide 3-décénoïque et son utilisation | |
JP7354246B2 (ja) | ピロロピリミジン骨格を有する新規なリン酸エステル化合物又はその薬学的に許容可能な塩 | |
EP1185540B1 (fr) | Complexes dimeres de ruthenium pouvant etre utilises en tant qu'agents antineoplasiques et antimetastasiques | |
US20130018028A1 (en) | Bi-(indole-2-aceto)-iron II (Ferrous Indole Acetate) | |
WO2006125323A1 (fr) | Nouveaux inhibiteurs de la pyruvate kinase comme agents therapeutiques anticancereux | |
WO2024089683A1 (fr) | Conjugués médicamenteux anticancéreux | |
JPH0373525B2 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07865644 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07865644 Country of ref document: EP Kind code of ref document: A1 |